Cognitive efficacy of quetiapine in early-onset first-episode psychosis: A 12-week open label trial

Psychiatric Quarterly

Volumn 83, Issue 3, 2012, Pages 311-324

  Urben, Sébastien ^a   Baumann, Pierre ^b   Barcellona, Sandra ^a   Hafil, Muriel ^a   Preuss, Ulrich ^c,d   Peter Favre, Claire ^a   Clarke, Stéphanie ^a   Halfon, Olivier ^a   Holzer, Laurent ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^c Kinder und Jugendpsychiatrische Poliklinik   (Switzerland)

^d Department of Pediatrics   (Germany)

Author keywords

Adolescence; Antipsychotic treatment; Cognition; Cognitive enhancer; Neuropsychology; Psychosis; Quetiapine; Schizophrenia

Indexed keywords

QUETIAPINE;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ARTICLE; ATTENTION; BRIEF PSYCHOTIC DISORDER; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; DELUSIONAL DISORDER; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXECUTIVE FUNCTION; FEMALE; HUMAN; INHIBITION (PSYCHOLOGY); LONG TERM MEMORY; LOW DRUG DOSE; MALE; NEUROPSYCHOLOGICAL TEST; OPEN STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SHORT TERM MEMORY; SYMPTOM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VELOCITY; VERBAL MEMORY;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84866742322     PISSN: 00332720     EISSN: 15736709     Source Type: Journal    
DOI: 10.1007/s11126-011-9201-3     Document Type: Article

References (57)

1. APA: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th edn. Washington, DC, American Psychiatric Association, 1994
2. Asarnow RF, Asamen J, Granholm E, et al.: Cognitive/neuropsychological studies of children with a schizophrenic disorder. Schizophrenia Bulletin 20:647-669, 1994
3. Holzer L, Chinet L, Jaugey L, et al.: Detection of cognitive impairment with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in adolescents with psychotic symptomatology. Schizophrenia Research 95:48-53, 2007
4. Kenny JT, Friedman L, Findling RL, et al.: Cognitive impairment in adolescents with schizophrenia. American Journal of Psychiatry 154:1613-1615, 1997
5. Kumra S, Wiggs E, Bedwell J, et al.: Neuropsychological deficits in pediatric patients with childhoodonset schizophrenia and psychotic disorder not otherwise specified. Schizophrenia Research 42:135-144, 2000
6. Rhinewine JP, Lencz T, Thaden EP, et al.: Neurocognitive profile in adolescents with early-onset schizophrenia: Clinical correlates. Biological Psychiatry 58:705-712, 2005
7. Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 153:321-330, 1996
8. Hofer A, Baumgartner S, Bodner T, et al.: Patient outcomes in schizophrenia II: The impact of cognition. European Psychiatry 20:395-402, 2005
9. Robles O, Zabala A, Bombin I, et al.: Cognitive Efficacy of quetiapine and olanzapine in early-onset first-episode psychosis. Schizophrenia Bulletin 37:405-415, 2011
10. Riedel M, Spellmann I, Strassnig M, et al.: Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience 257:360-370, 2007
11. Velligan DI, Newcomer J, Pultz J, et al.: Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophrenia Research 53:239-248, 2002
12. Zhong KX, Sweitzer DE, Hamer RM, et al.: Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. Journal of Clinical Psychiatry 67:1093-1103, 2006
13. Tandon R: Improvement without impairment: A review of clinical data for quetiapine in the treatment of schizophrenia. Journal of Clinical Psychopharmacology 23:S15-S20, 2003
14. Andersen R, Fagerlund B, Rasmussen H, et al.: Cognitive effects of six months treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia. Psychiatry Research 187:49-54, 2011
15. Quintana H, Wilson MS 2nd, Purnell W, et al.: An open-label study of olanzapine in children and adolescents with schizophrenia. Journal of Psychiatric Practice 13:86-96, 2007
16. Sanford M, Keating GM: Aripiprazole: In adolescents with schizophrenia. Paediatric Drugs 9:419-423, 2007
17. Arango C, Robles O, Parellada M, et al.: Olanzapine compared to quetiapine in adolescents with a first psychotic episode. European Child and Adolescent Psychiatry 18:418-428, 2009
18. Findling RL, McNamara NK, Youngstrom EA, et al.: A prospective, open-label trial of olanzapine in adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry 42:170-175, 2003
19. Dittmann RW, Meyer E, Freisleder FJ, et al.: Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: Results from a large, prospective, open-label study. Journal of Child and Adolescent Psychopharmacology 18:54-69, 2008
20. McConville BJ, Arvanitis LA, Thyrum PT, et al.: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. Journal of Clinical Psychiatry 61:252-260, 2000
21. Shaw JA, Lewis JE, Pascal S, et al.: A study of quetiapine: Efficacy and tolerability in psychotic adolescents. Journal of Child and Adolescent Psychopharmacology 11:415-424, 2001
22. Swadi HS, Craig BJ, Pirwani NZ, et al.: A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15-to 18-year-old adolescents. International Clinical Psychopharmacology 25:1-6, 2010
23. Richelson E: New antipsychotic drugs: How do their receptor-binding profiles compare? Journal of Clinical Psychiatry 71:1243-1244, 2010
24. Jensen NH, Rodriguiz RM, Caron MG, et al.: N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33:2303-2312, 2008
25. Yatham LN, Kennedy SH, Schaffer A, et al.: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disorder 11:225-255, 2009
26. Chamberlain SR, Muller U, Robbins TW, et al.: Neuropharmacological modulation of cognition. Current Opinion in Neurology 19:607-612, 2006
27. Nathan PJ, Sitaram G, Stough C, et al.: Serotonin, noradrenaline and cognitive function: A preliminary investigation of the acute pharmacodynamic effects of a serotonin versus a serotonin and noradrenaline reuptake inhibitor. Behavioural Pharmacology 11:639-642, 2000
28. Holzer L, Preuss U, Baumgartner L, et al.: Quetiapine in adolescents with non-affective psychotic disorders: An open-label trial. Pharmacopsychiatry 44:87-95, 2011
29. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13:261-276, 1987
30. Guy W: ECDEU Assessment Manual. Rockville, MD, US Department of Health, Education and Welfare, 1976
31. Reitan R, Wolfson D: The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, AZ, Neuropsychology Press, 1985
32. Asarnow RF, Nuechterlein KH, Subotnik KL, et al.: Neurocognitive impairments in nonpsychotic parents of children with schizophrenia and attention-deficit/hyperactivity disorder: The University of California, Los Angeles Family Study. Archives of General Psychiatry 59:1053-1060, 2002
33. Nuechterlein KH: Vigilance in Schizophrenia and Related Disorders. In: Steinhauer SR, Gruzelier JH, Zubin J (Eds) Handbook of Schizophrenia: Neuropsychology, Psychophysiology and Information Processing. New York, Elsevier Science Inc., 1991
34. Hebb DO: Distinctive Features of Learning in the Higher Animal. In: Delafresnaye JE (Ed) Brain Mechanisms and Learning. New York, Oxford University Press, 1961
35. Corsi PM: Human Memory and the Medial Temporal Region of the Brain. Dissertation Abstracts International 34:891B (University Microfilms No. AAI05-77717), 1972
36. Rey A: L'examen clinique en psychologie. Paris, Presses Universitaires de France, 1964
37. Osterrieth, P: Le test de copie d'une figure complexe: Contribution à l'étude de la perception et de la mémoire. Archives de Psychologie, Geneva 30:205-220, 1944
38. Spreen O, Strauss E: A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, 2nd edn. New York, Oxford University Press, 1998
39. Bolognini M, Plancherel B, Laget J, et al.: Evaluation of the adolescent drug abuse diagnosis instrument in a Swiss sample of drug abusers. Addiction 96:1477-1484, 2001
40. Buchanan RW, Davis M, Goff D, et al.: A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophrenia Bulletin 31:5-19, 2005
41. Gothelf D, Apter A, Reidman J, et al.: Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. Journal of Neural Transmission 110:545-560, 2003
42. Miyake A, Friedman NP, Emerson MJ, et al.: The unity and diversity of executive functions and their contributions to complex "Frontal Lobe" tasks: A latent variable analysis. Cognitive Psychology 41:49-100, 2000
43. Good KP, Kiss I, Buiteman C, et al.: Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: An interim analysis. British Journal of Psychiatry Supplement 43:s45-s49, 2002
44. Kivircik Akdede BB, Alptekin K, Kitis A, et al.: Effects of quetiapine on cognitive functions in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 29:233-238, 2005
45. Arvanitis LA, Miller BG: Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biological Psychiatry 42:233-246, 1997
46. Small JG, Hirsch SR, Arvanitis LA, et al.: Quetiapine in patients with schizophrenia. A high-and lowdose double-blind comparison with placebo. Seroquel Study Group. Archives of General Psychiatry 54:549-557, 1997
47. Kahn RS, Fleischhacker WW, Boter H, et al.: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 371:1085-1097, 2008
48. Robinson DG, Woerner MG, Alvir JM, et al.: Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 156:544-549, 1999
49. Robinson DG, Woerner MG, Delman HM, et al.: Pharmacological treatments for first-episode schizophrenia. Schizophrenia Bulletin 31:705-722, 2005
50. Suhara T, Okubo Y, Yasuno F, et al.: Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Archives of General Psychiatry 59:25-30, 2002
51. Riedel M, Muller N, Strassnig M, et al.: Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatric Disease and Treatment 3:219-235, 2007
52. Kapur S, Zipursky R, Jones C, et al.: Relationship between dopamine D (2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry 157:514-520, 2000
53. Kapur S, Zipursky R, Jones C, et al.: A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Archives of General Psychiatry 57:553-559, 2000
54. Tandon R, Milner K, Jibson MD: Antipsychotics from theory to practice: Integrating clinical and basic data. Journal of Clinical Psychiatry 60(Suppl 8):21-28, 1999
55. Nikisch G, Baumann P, Wiedemann G, et al.: Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: Correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. Journal of Clinical Psychopharmacology 30:496-503, 2010
56. Holzer L, Halfon O: Normalization of impaired cognitive functions failed to improve clinical symptomatology in a schizophrenic patient. European Psychiatry 19:384-386, 2004
57. Conway Greig T, Nicholls SS, Wexler BE, et al.: Test-retest stability of neuropsychological testing and individual differences in variability in schizophrenia outpatients. Psychiatry Research 129:241-247, 2004